Vaso Stock Declines Post Q4 Earnings Despite Revenue Growth

Shares of Vaso Corporation VASO have lost 0.1% since the company reported its earnings for the quarter ended Dec. 31, 2025, underperforming the S&P 500 Index, which gained 3.9% over the same period. Over the past month, the stock lost 6.3% compared with a 3.5% dip in the broader index.

VASO’s Earnings Snapshot

For the fourth quarter of 2025, Vaso reported revenues of $27.02 million, essentially flat compared with $27.04 million in the year-ago quarter. Gross profit increased 2.3% year over year to $17.6 million from $17.2 million, reflecting improved margins. However, quarterly net income declined 47.4% to $1.1 million from $2.1 million in the prior-year period, primarily due to higher selling, general and administrative (SG&A) expenses and a goodwill impairment charge.

On a full-year basis, revenue rose 2.7% to $89.1 million from $86.8 million, while net income increased 64.9% to $1.6 million from $0.9 million in 2024.

Segmentally, IT revenue declined 7.9% in the quarter to $10.2 million due to the divestiture of the healthcare IT unit, while professional sales service revenue grew 6.3% to $15.9 million, driven by higher equipment deliveries and commission rates. Equipment segment revenue fell 7.6% to $851 thousand due to weaker China sales.

Vaso’s Segment Performance and Margins

The professional sales service segment remained the primary growth driver, benefiting from increased equipment deliveries and higher blended commission rates. For the full year, segment revenue rose 6.9% to $44.2 million from $41.3 million, contributing significantly to overall top-line expansion. In contrast, the IT segment saw a modest decline of 1.1% annually to $42.5 million from $42.9 million, reflecting the impact of the November 2025 divestiture of the healthcare IT business. The equipment segment continued to lag, with revenue down 1.5% for the year due to lower volumes in China, partially offset by growth in U.S.-based SaaS offerings.

Gross margin improvement supported profitability, with full-year gross profit increasing 5% to $54.7 million from $52.1 million. However, operating performance was pressured by higher costs, as SG&A expenses rose 6.6% to $52.2 million from $48.9 million, driven mainly by increased personnel and travel expenses in the sales segment.

VASO’s Cash Flow and Balance Sheet Strength

Vaso generated a strong operating cash flow of $9.3 million in 2025, up from $3.3 million in 2024, supported by higher order bookings and favorable timing of receivables. The company ended the year with $35.1 million in cash and cash equivalents, up from $26.3 million a year earlier, highlighting a solid liquidity position. Deferred revenue increased 10.6% to $38.6 million from $34.9 million, reflecting strong order activity in the professional sales service segment and providing visibility into future revenue recognition.

Vaso’s Management Commentary and Key Drivers

Management highlighted record annual revenue and emphasized sustained top-line growth alongside profitability improvements. The increase in net income for the year was attributed to higher gross profit, tax benefits and a gain on the sale of the healthcare IT business unit, partially offset by goodwill impairment and rising operating costs. VASO also noted ongoing efforts to realign its business portfolio to enhance efficiency and profitability.

Despite these positives, adjusted EBITDA turned negative $1.5 million in 2025 against a positive $1 million in 2024, indicating underlying pressure on operating earnings. The deterioration was largely linked to lower operating income and increased expenses.

Factors Influencing VASO’s Performance

Several factors shaped Vaso’s results during the period. The divestiture of the healthcare IT business reduced IT segment revenue but also contributed to gains and tax benefits. Meanwhile, higher SG&A expenses — particularly in sales and IT operations — offset gains from improved gross margins. Additionally, a goodwill impairment charge in the IT segment weighed on quarterly profitability.

Growth in the professional sales service segment was supported by strong demand for GE HealthCare equipment and improved commission structures, underscoring the importance of this segment to VASO’s overall performance.

Vaso’s Other Developments

A key development during the quarter was the sale of Vaso’s healthcare IT business unit in November 2025, which significantly impacted segment performance and financial comparisons. The transaction contributed to gains recognized during the year and reflects management’s broader strategy to streamline operations and focus on higher-margin business areas.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research